Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00518869
Other study ID # PH-CP010
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date September 2007
Est. completion date December 2009

Study information

Verified date November 2023
Source PhytoHealth Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to evaluate the efficacy and safety of PG2 as a complementary treatment to conventional chemotherapy among NSCLC patients. In reference to previous studies, "Clinical Benefit Response" and "Incidence of Grade III plus VI Neutropenia" will be used as the primary endpoints in this study. Clinical Benefit Response is a metric measurement including change in cancer or cancer treatment related "fatigue" which is related to chronic fatigue syndrome (CFS), change in karnofsky performance status and change in weight. The secondary endpoints include patient's global quality of life, and the blood c-reactive protein level which is related to weight change, tumor response, survival time, incidences of myelosuppression (including neutropenia, anemia and thrombocytopenia) and the related G-CSF and antibiotics consumption.


Description:

This is a multi-center, double-blind, randomized and placebo-controlled study to evaluate complementary effect of PG2 in patients with advanced non-small-cell lung cancer under conventional chemotherapy. Patients with Stage IIIb-IV non-small-cell lung cancer will be screened by inclusion and exclusion criteria and only eligible patients will be enrolled into this study. All enrolled patients will be randomized to PG2 or Placebo arm and will receive the cisplatin-based chemotherapy treatment (Cisplatin 75mg/m2 and Docetaxel 60mg/m2 on Day1) during the first three 21-day chemo-cycles. Chemo regimen modification is allowable, as usual, in case of disease progression or unacceptable toxicity (see Section 6). After randomization, each patient will be administered with PG2 or placebo for 4 days in the 1st week, 3 days in the 2nd week and 3 days in the 3rd week of each chemo-cycle for 3 cycles (Dosing Schedule in Section 6). Total 10 doses will be given in each cycle.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date December 2009
Est. primary completion date June 2008
Accepts healthy volunteers No
Gender All
Age group 17 Years to 75 Years
Eligibility Inclusion Criteria: - Signed the informed consent form. - 18 ~ 75 years old - Locally advanced or metastatic with inoperable stage IIIb-IV non-small-cell lung cancer. - Chemo/Radio naive patient - Karnofsky Performance Scores ? 70. - Adequate bone marrow reserve. - Adequate liver function. - Adequate renal function. - Women with childbearing potential are willing to take contraception measures through the whole treatment course. - Life expectancy ? 3 months - Patient must be willing and able to complete quality of life questionnaires. Exclusion Criteria: - Female patients are pregnant or breast-feeding - Patients have brain metastases, stroke or major psychiatric disease. - Patients with uncontrolled systemic disease such as active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus. - Patients have enrolled or have not yet completed other investigational drug trials within 30 days before randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PG2
500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.

Locations

Country Name City State
Taiwan Changhua Christian Hospital Changhua
Taiwan Chang-Gung Memorial Hospital - Kaoshiung Kaohsiung
Taiwan Kaoshiung Medical University Hospital Kaohsiung
Taiwan Chang-Gung Memorial Hospital, Linkou Linkou
Taiwan China Medical University Hospital Taichung
Taiwan Taichung Veterans General Hospital Taichung
Taiwan National Cheng-Kung University Hospital Tainan
Taiwan Mackay Memorial Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei
Taiwan Tri-Service General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
PhytoHealth Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Benefit Response within and between each chemo-cycle (21 days)
Primary Incidence of Grade III plus IV Neutropenia within and between each chemo-cycle (21 days)
Secondary Quality of Life Assessments within and between each chemo-cycle (21 days)
Secondary The blood c-reactive protein level which is related to weight change within and between each chemo-cycle (21 days)
Secondary Tumor Response 3 months
Secondary Survival Time one year
Secondary Incidences of myelosuppression and the related G-CSF consumption and antibiotics consumption within and beween each chemo-cycle (21 days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT06238557 - Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT05472935 - Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers N/A
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT05546931 - Mobile Health Program for Rural Hypertension N/A
Active, not recruiting NCT04746664 - Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia N/A
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Active, not recruiting NCT05903638 - A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT03813420 - Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level N/A
Recruiting NCT05550545 - Infant RSV Infections and Health-related Quality of Life of Families
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Recruiting NCT05233020 - Robotic Versus Hybrid Assisted Ventral Hernia Repair N/A
Terminated NCT03304184 - The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life Phase 3
Completed NCT05063305 - Probiotics, Immunity, Stress, and QofL N/A
Recruiting NCT05380856 - Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction N/A